The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
Closed
Recruitment start date:
01/07/2014
Funder:
MRC
Sponsor:
Chief Investigator:
Prof Persis Amrolia
Recruitment target:
32
EudraCT number:
Contact details:
ctc.icat@ucl.ac.uk
Lay summary:
ICAT
Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant.
Description
Design: ICAT is a multi-centre randomised phase II trial in adult patients with an underlying haematological malignancy undergoing unrelated donor peripheral blood stem cell transplant with Alemtuzumab-based conditioning. Patients will be randomly allocated 2:1 in favour of those receiving the ATIMP (CD25/71 allodepleted donor T-cells) compared with an internal control group receiving standard of care therapy. 
Treatment:
Patients on the ATIMP arm will undergo an unstimulated leucapheresis for generation of mature denditric cells two weeks prior to their SCT. The SCT donor will either undergo unstimulated leucapheresis or a 500ml whole blood draw for the generation of peripheral blood stem cells. The isolated donor peripheral blood stem cells will then be co-cultured with the irradiated recipient mature denditric cells and allodepletion performed using immunomagnetic CD25/71 negative selection using the CliniMACs system.

The allodepleted donor T cells will be infused intravenously at increasing doses (105 /kg at day 30 post-SCT [+/- 10 days], 3 x 105 /kg at day 60 [+/- 10 days] and 106 /kg at day 90 [+/- 10 days]) at monthly intervals post-SCT until either their circulating CD3 count is normal (>700/µL) or they develop acute GVHD > Grade I. Those in the control arm will receive identical supportive care, but will not receive the ATIMP.

Key inclusion/exclusion criteria:
Inclusion:
Underlying haematological malignancy
Planned allogeneic peripheral blood stem cell transplantation from a 9/10 or 10/10 human leukocyte antigen (HLA) matched unrelated donor, using an Alemtuzumab-based conditioning protocol
Absence of acute GVHD > Grade I

Exclusion:
Patients who are serologically positive for Hepatitis B, C or HIV pre-SCT

Duration of recruitment: 3 years
Aim
To determine whether adoptive immunotherapy with CD25/71 allodepleted donor T-cells can be safely used to improve T-cell reconstitution after unrelated donor stem cell transplant (SCT)
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us